Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Chinese Drug Regulators Issue New Rules To Increase Safety Standards Of Vaccines

This article was originally published in PharmAsia News

Executive Summary

BEIJING - In the wake of a series of vaccine scandals across China during the past year, triggering sometimes fatal adverse events, China's State FDA is strengthening rules governing the manufacturing, distribution and inspection of vaccines nationwide
Advertisement

Related Content

Are China’s Vaccines Ready For The World?
What Multinational Companies Need To Know About China's New GMP Regs - Webinar (Part 2 of 2)
GSK Buys Out Partner Neptunus' Stake in Chinese Vaccines Joint Venture
China's Simcere Looks To Move Past Vaccine Troubles, Focuses On New GMP Requirements, Partnering With Big Pharma
Leading Chinese Vaccine Developer Sinovac Conducts Technical Exchanges With Gates Foundation On Rotavirus Vaccine
China's Leading Vaccine Developer Sees Sales Slashed Due To Popular Backlash Against Series Of Scandals
Hit Collaterally By Popular Backlash Following Vaccine Scandals, China's Sinovac Could Exploit High Quality Standards To Emerge As Winner
Massive Vaccine Joint Venture With Canada's Microbix Will Help China Prepare Defense Arsenal Against Viral Threats Of The Future
Massive Vaccine Joint Venture With Canada's Microbix Will Help China Prepare Defense Arsenal Against Viral Threats Of The Future
China’s 2009 Regulatory Changes Will Affect Makers of Drugs, APIs and Devices
Advertisement
UsernamePublicRestriction

Register

SC077171

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel